ClinicalTrials.gg
Not yet recruitingNCT07947680Updated Nov 19, 2026

A Study on the Safety and Efficacy of Adenosylcobalamin in Patients With Declining Ovarian Function

A Phase 4 interventional study of adenosylcobalamin in Premature Ovarian Insufficiency (POI) and Diminished Ovarian Reserve (DOR), sponsored by Tongji Hospital. Not yet recruiting. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Tongji Hospital · Phase 4, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 39 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to learn if adenosylcobalamin works to treat POI and DOR. It will also learn about the safety of adenosylcobalamin. The main questions it aims to answer are:

Can adenosylcobalamin improve the clinical symptoms, signs, and hormone levels of patients with POI and DOR? What is the safety of adenosylcobalamin?

Participants will:

Take adenosylcobalamin three times a day for 3 months Visit the clinic for 5 checkups and tests

02

Conditions studied

  • Premature Ovarian Insufficiency (POI)
  • Diminished Ovarian Reserve (DOR)
03

In context

Primary Ovarian Insufficiency

182 studies on the registry are indexed under Primary Ovarian Insufficiency; 49 are open to participants now.

This study's planned enrollment of 48 is close to the median of 48 across 114 interventional studies indexed under Primary Ovarian Insufficiency.

Browse Primary Ovarian Insufficiency studies →

Lead sponsor

Tongji Hospital is the lead sponsor of 392 studies on the registry; 213 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Premature Ovarian Insufficiency (POI): Age \< 40 years old, with two consecutive basal FSH levels ≥ 25 U/L spaced 4 weeks apart, decreased anti-müllerian hormone (AMH), and clinical manifestations of oligomenorrhea or amenorrhea.

(2) Diminished ovarian reserve (DOR): Age \< 40 years old, with a decrease in the number and/or quality of oocytes in the ovary, and/or accompanied by a decreased AMH level (\< 1.1 ng/mL), and/or a reduced number of antral follicles (AFC) (\< 6) and/or an elevated basal FSH level (> 10 U/L).

Exclusion criteria

Exclusion Criteria:

  1. Abnormal uterine bleeding of unknown cause;
  2. Presence of ovarian/appendage masses ≥ 4 cm, uterine adenomyosis, uterine adenomyoma/uterine fibroids ≥ 4 cm;
  3. BI-RADS rating of breast ultrasound ≥ 4;
  4. Presence of precancerous lesions or having malignant tumors;
  5. Liver and kidney function indicators (, AST, Urea, Cr) exceed the reference values and have not returned to normal after re-examination;
  6. Complicated with severe primary diseases in the nervous, circulatory, respiratory, digestive, urinary or hematopoietic systems, or patients with mental disorders;
  7. Have received systemic hormone replacement therapy within the last 2 months;
  8. Are participating in other clinical trials or have participated in other clinical trials within the last 1 month;
  9. Have a recent fertility requirement;
  10. Other patients deemed unsuitable for participation in this study by the researchers.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    POI and DOR

    Drug: adenosylcobalamin

Interventions

  • DrugCobamamideStudies of CobamamideCobamamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Take oral adenosylcobalamin tablets, 0.5mg per dose, three times a day. Continue the treatment for 12 weeks.

06

What researchers measure

Primary outcomes

  1. anti-müllerianhormone

    The serum anti-müllerianhormone(AMH) level is the primary indicator for evaluating ovarian reserve function and is used for diagnosing POI and DOR. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function.

    Time frame: Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.

  2. sex hormones

    The sex hormone tests include estradiol, follicle-stimulating hormone(FSH), luteinizing hormone(LH), progesterone, testosterone and prolactin. Among them, FSH is the main indicator for diagnosing POI and DOR. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function.

    Time frame: Serum tests will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.

  3. antral follicles

    The number of antral follicles refers to the total count of antral follicles observed bilaterally in the ovaries through transvaginal ultrasound examination during the early stage of follicular development. Studies have confirmed that the number of antral follicles is related to the size of the primordial follicle pool, and it can be used to assess ovarian reserve function. In this clinical trial, adenosylcobalamin was used to evaluate its effectiveness in improving ovarian function.

    Time frame: Color Doppler ultrasound examination will be conducted at the 1st, 2nd, 4th, 8th and 12th weeks of medication.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947680
Lead sponsor
Tongji Hospital
Responsible party
Shixuan Wang (professor, Tongji Hospital) — Principal investigator
First posted
Nov 19, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Liru Xue
Contact
751400767@qq.com
CN 18727297670

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cobamamide

Start the discussion